Improving Adherence to Adjuvant Endocrine Therapy in Breast Cancer Through a Therapeutic Educational Approach: A Feasibility Study .
To develop and test the feasibility of a tailored therapeutic educational program, with the aim of improving adherence to oral endocrine adjuvant chemotherapy in women with breast cancer.  .



A qualitative study to identify educational needs and a feasibility study assessing the efficacy of the program. .



A comprehensive cancer center, the Lucien Neuwirth Cancer Institute in Saint-Priest-en-Jarez, France. .



Two consecutive samples (N = 11, N = 6) of women taking adjuvant oral endocrine chemotherapy for breast cancer.  .



A mixed qualitative and quantitative method was used. The participants' representations of disease and treatment were explored through one-on-one interviews and then translated into educational needs, which were used to develop a tailored therapeutic education program. The pilot study evaluated the reach and efficacy using before-and-after comparisons.  .



Educational objectives, knowledge, trust in the treatment, and anxiety. .



Five educational objectives (acquiring knowledge, improving communication skills, managing anxiety, managing side effects, and improving adherence) were identified through 11 interviews. A three-session program was developed. Eight of the 23 patients invited to participate in a pilot study accepted, and six completed the intervention. Knowledge improved from 38.9 of 100 preintervention to 69.4 of 100 postintervention (p = 0.045). Trust in treatment showed a trend to improvement from 5.5 of 10 to 8 of 10 (p = 0.14), but anxiety did not change significantly; anxiety went from 6 to 7 (p = 0.88). .



Results from the feasibility study showed promising efficacy for the educational objectives and provided information about how the program could be improved.  .



Tailored educational programs conducted by trained nurses may help patients to adhere to and live with the effects of endocrine therapy.
Lucien Neuwirth Cancer Institute.
Aurélie
A
Bourmaud
Lucien Neuwirth Cancer Institute.
Vanessa
V
Rousset
Lucien Neuwirth Cancer Institute.
Véronique
V
Regnier-Denois
Lucien Neuwirth Cancer Institute.
Olivier
O
Collard
Lucien Neuwirth Cancer Institute.
Jean-Philippe
JP
Jacquin
Lucien Neuwirth Cancer Institute.
Yacine
Y
Merrouche
Lucien Neuwirth Cancer Institute.
Joelle
J
Lapoirie
Lucien Neuwirth Cancer Institute.
Fabien
F
Tinquaut
Geneva University Hospital.
Laurence
L
Lataillade
Lucien Neuwirth Cancer Institute.
Franck
F
Chauvin
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D052244:Endocrine Disruptors / Q000008:administration & dosage*; D005240:Feasibility Studies; D005260:Female; D005602:France; D006801:Humans; D008875:Middle Aged; D009859:Oncology Nursing / Q000379:methods*; D010349:Patient Compliance / Q000523:psychology*; D010353:Patient Education as Topic; D010865:Pilot Projects
D052244:Endocrine Disruptors
adherence; adjuvant endocrine therapy; breast cancer; empowerment; quantitative and qualitative mixed method; side effects; therapeutic educational program